Anastomotic leak · patients with Bowel resection
It is very uncertain whether single layer gastrointestinal anastomosis changes anastomotic leak Odds ratio compared with double layer gastrointestinal anastomosis (very low certainty).
1 finding from 1 review
Anastomosis time Mean difference · patients with Bowel resection
1 finding from 1 review
Hospital length of stay (high‐risk surgical patients) · patients with Bowel resection
1 finding from 1 review
Mortality Odds ratio · patients with Bowel resection
Single layer gastrointestinal anastomosis showed no clear difference in mortality Odds ratio compared with double layer gastrointestinal anastomosis (low certainty).
1 finding from 1 review
Major complications · patients with Bowel resection
Single layer gastrointestinal anastomosis showed no clear difference in major complications Odds ratio compared with double layer gastrointestinal anastomosis (low certainty).
1 finding from 1 review
Anastomotic leak in high quality trials Odds ratio · patients with Bowel resection
Single layer gastrointestinal anastomosis showed no clear difference in anastomotic leak in high quality trials Odds ratio compared with double layer gastrointestinal anastomosis (moderate certainty).
1 finding from 1 review
Anastomotic leak in poor quality trials Odds ratio · patients with Bowel resection
It is very uncertain whether single layer gastrointestinal anastomosis changes anastomotic leak in poor quality trials Odds ratio compared with double layer gastrointestinal anastomosis (very low certainty).
1 finding from 1 review
Number of participants with 3 or more adenomas (in studies with single intubation) · people undergoing colonoscopy for the detection of polyps
Chromoscopy may leads to higher number of participants with 3 or more adenomas (in studies with… compared with conventional colonoscopy (low certainty).
1 finding from 1 review
Overall survival (3 years) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).
1 finding from 1 review
Disease-free survival · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
It is very uncertain whether combination chemotherapy changes disease‐free survival (3 years) compared with single‐agent chemotherapy (very low certainty).
1 finding from 1 review
Complete response rate after preoperative chemoradiation (ypCR) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy leads to higher complete response rate after preoperative chemoradiation (ypCR) compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Toxicity ‐ early adverse events G3/4 · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Metastases intra‐abdominal · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy showed no clear difference in metastases intra‐abdominal compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Radiotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to lower radiotherapy compliance compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Chemotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy leads to lower chemotherapy compliance compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Overall survival (Death) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).
1 finding from 1 review
Grade 3/4 diarrhea · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines probably leads to lower grade 3/4 diarrhea compared with single agent IRI (moderate certainty).
1 finding from 1 review
Grade 3/4 nausea · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in grade 3/4 nausea compared with single agent IRI (low certainty).
1 finding from 1 review